



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Talquetamab

Cat. No.:	HY-P99394
CAS No.:	2226212-40-2
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity <sup>[1][2]</sup> .	
<b>In Vitro</b>	Talquetamab (0.00128-4.0 µg/mL, 48 h) effectively induces multiple myeloma cell lysis and leads to a significant increase in the proportion of activated CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells, as well as to a dose-dependent increase in the levels of granzyme B and inflammatory cytokines such as IL-6, IL-8 and TNF-α <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Talquetamab (JNJ-64407564) (0.1-50 µg, s.c. or i.v.) has significant antitumor activity in H929 and MM mouse models <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Female NSG mice with H929 cells <sup>[2]</sup>
	Dosage:	0.1-10 µg (0.005 mg/kg)
	Administration:	Subcutaneous injection; on days 0, 3, 5, 7, and 10
	Result:	Completely blocked tumor formation at 1 µg and 10 µg doses.
	Animal Model:	Female NSG mice with human MM cells <sup>[2]</sup>
	Dosage:	0.1-50 µg (0.005 mg/kg)
	Administration:	Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36
	Result:	Significantly inhibited tumor growth by 65% at the dose of 1µg and showed significant anti-tumor activity at 10 and 50 µg with complete tumor regression.

### REFERENCES

[1]. Christie P M Verkleij, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021

---

Apr 27;5(8):2196-2215.

[2]. Kodandaram Pillarisetti, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020 Apr 9;135(15):1232-1243.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA